Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building the Right Foundation: An Interview with Mark McClellan

This article was originally published in RPM Report

Executive Summary

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

You may also be interested in...



FDA Commissioner Search: Myths And Reality

Speculation about the next FDA head is well under way, but before it gets out of hand, here are five rules of thumb to keep in mind.

Who Will Run CMS Under Obama?

Part D changes, and especially price negotiation, are a high priority for some in Congress. Who might be asked to make Medicare work in the next administration?

Who Will Run FDA Under Obama?

Steve Nissen has been getting the most attention, but there are plenty of other possibilities. Here are some of the names we’ve heard.

Related Content

Topics

UsernamePublicRestriction

Register

PS080422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel